• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Treatment-free remission of chronic myeloid leukemia possible after second-line nilotinib

byEvelyn NguyenandDeepti Shroff Karhade
February 20, 2018
in Chronic Disease, Oncology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Phase 2, open-label study results suggest that treatment-free remission (TFR) of chronic myeloid leukemia (CML) for ≥48 weeks can be reached by over half of patients who have reached deep molecular response (DMR) after ceasing second-line nilotinib treatment.

2. The authors suggest that for patients who do not reach sustained DMR with imatinib, changing to nilotinib may help more patients reach TFR.

Evidence Rating Level: 1 (Excellent)     

Study Rundown: A rising treatment goal for CML is TFR, which is the maintenance of response after ceasing tyrosine kinase inhibitor (TKI) therapy.  Benefits of TFR include avoiding treatment side effects, decreased risk of toxicity from long-term TKI use, and family planning possibilities.  This Phase 2, open-label study assessed TFR after termination of second-line nilotinib therapy.  Researchers studied 163 patients who had reached sustained DMR following a change from imatinib to nilotinib to see if these patients could stay in remission without TKI.  Researchers found that 58% of patients maintained TFR at the primary end point of 48 weeks.  At 96 weeks, 53% of patients maintained TFR.  The results indicate that TFR can be attained by CML patients who have reached DMR after ceasing second-line nilotinib treatment.  The authors suggest that for patients who do not reach sustained DMR with imatinib, changing to nilotinib may help more patients reach TFR.  The authors advised that any treatment switching decisions should factor in both risks and benefits of TKIs.

This was the first large prospective study to examine TFR with a specific focus on patients who attained sustained DMR only following a change from imatinib to nilotinib.  Study limitations included a heterogeneous patient group and the inability to compare between patients continuing or stopping treatment.

Click to read the study in Annals of Internal Medicine

RELATED REPORTS

#VisualAbstract ENESTnd: Frontline nilotinib therapy shows improvement in long-term efficacy outcomes for patients in the chronic phase of newly diagnosed chronic myeloid leukemia

Small-molecule drug reduces chemoresistance of chronic myelogenous leukemia cells [PreClinical]

Relevant Reading: The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up

In-Depth [prospective cohort]: Researchers screened 256 patients between December 2012 and December 2013.  The 163 enrolled patients were ≥18 years of age, had CML in chronic phase, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, were getting TKI treatment for ≥3 years (imatinib for >4 weeks, followed by nilotinib for ≥2 years), and had reached MR4.5 (a molecular response benchmark of BCR-ABL1 ≤0.0032% on the International Scale) while taking nilotinib after a switch from imatinib treatment.  Of the 163 enrollees, 126 were qualified for entrance to the TFR phase and to halt nilotinib treatment.  Of these patients, 73 (58%) of patients maintained TFR at the primary end point of 48 weeks.  At 96 weeks, 67 (53%) of patients maintained TFR.  Fifty-five of the 56 patients resumed nilotinib treatment regained major molecular response (MMR) (BCR-ABL1 ≤0.1%) or better.  None of these patients had CML advancement to the accelerated phase or blast crisis.  In the first 48 weeks after terminating nilotinib, musculoskeletal pain was more common.  In comparison to the TFR group, the 37 patients without TFR entry had a greater period from diagnosis of CML to study initiation, a longer duration of prior TKI treatment (mainly due to a longer period of imatinib treatment), and a briefer MR4.5 time before starting the study.

Image: CC/Wiki

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chronic myelogenous leukemiaNilotinib
Previous Post

Opioid use associated with increased risk of invasive pneumococcal disease

Next Post

Breast cancer screening using MRI versus mammography associated with more biopsies but lower cancer yield

RelatedReports

#VisualAbstract ENESTnd: Frontline nilotinib therapy shows improvement in long-term efficacy outcomes for patients in the chronic phase of newly diagnosed chronic myeloid leukemia
StudyGraphics

#VisualAbstract ENESTnd: Frontline nilotinib therapy shows improvement in long-term efficacy outcomes for patients in the chronic phase of newly diagnosed chronic myeloid leukemia

February 4, 2021
Severe subtype of acute lymphoblastic leukemia susceptible to FDA-approved kinase inhibitors
Oncology

Small-molecule drug reduces chemoresistance of chronic myelogenous leukemia cells [PreClinical]

December 29, 2015
Next Post
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ

Breast cancer screening using MRI versus mammography associated with more biopsies but lower cancer yield

Computed tomography improves diagnostic certainty in the emergency department

Complex government-mandated sepsis performance measures not shown to improve survival

Placebo formulation impacts effectiveness of pain control in osteoarthritis

Hydroxychloroquine shows no greater effectiveness than placebo for hand osteoarthritis pain

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
  • 2 Minute Medicine Rewind June 30, 2025
  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.